An International Atherosclerosis Society Position

The International Atherosclerosis Society brought together 15 cholesterol experts from around the world to create updated recommendations for managing dyslipidemia - a condition where you have unhealthy levels of fats (lipids) in your blood. These experts reviewed extensive research including population studies, genetic research, and clinical trials to develop evidence-based guidelines that can be applied globally.

The key finding from this international panel is that non-HDL cholesterol should be the primary target for treatment, rather than focusing solely on LDL ("bad") cholesterol. Non-HDL cholesterol includes all the cholesterol-carrying particles that can build up in your arteries and cause heart disease. The experts made different recommendations depending on whether someone is trying to prevent their first heart problem (primary prevention) or already has heart disease (secondary prevention).

For people without existing heart disease, the guidelines emphasize lifestyle changes - like improving diet, exercise, and weight management - as the first line of defense. Medications are recommended only for those at higher risk. For people who already have heart disease, the recommendations focus more heavily on cholesterol-lowering medications to reach optimal levels quickly.

What makes these guidelines particularly relevant for metabolic health is their emphasis on lifetime risk assessment and the connection to metabolic syndrome. The panel recognizes that managing cholesterol is part of a broader approach to metabolic health that can significantly impact longevity and quality of life. In clinical practice, these guidelines help physicians take a more personalized approach to cholesterol management, considering your individual risk factors, geographic location, and overall health profile rather than applying a one-size-fits-all approach.